Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy.
about
Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Predictors of overall survival ...... -PSMA-617 radioligand therapy.
@en
Predictors of overall survival ...... -PSMA-617 radioligand therapy.
@nl
type
label
Predictors of overall survival ...... -PSMA-617 radioligand therapy.
@en
Predictors of overall survival ...... -PSMA-617 radioligand therapy.
@nl
prefLabel
Predictors of overall survival ...... -PSMA-617 radioligand therapy.
@en
Predictors of overall survival ...... -PSMA-617 radioligand therapy.
@nl
P2093
P2860
P356
P1433
P1476
Predictors of overall survival ...... u-PSMA-617 radioligand therapy
@en
P2093
Carl Schlenkhoff
Florian C Gaertner
Markus Essler
Rolf Fimmers
Stefan Hauser
Stefan Hirzebruch
Stephan Schlolaut
Zool Hilmi Awang
P2860
P304
103108-103116
P356
10.18632/ONCOTARGET.21600
P407
P577
2017-10-07T00:00:00Z